Completed

BARDA IIIdentify Clinical Conditions That Increase Circulating DNA Levels

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

+ other Data

+ other Data

Collected from today forward - Prospective
OtherDNA Samples
Who is being recruted

Cardiovascular Diseases+14

+ Embolism

+ Heart Diseases

From 18 to 80 Years
See all eligibility criteria
How is the trial designed

Case-Control

Comparing exposures between individuals with and without disease in order to identify potential risk factors.
Observational
Study Start: October 2012
See protocol details

Summary

Principal SponsorUniversity of Florida
Last updated: November 21, 2018
Sourced from a government-validated database.Claim as a partner

Study start date: October 1, 2012

Actual date on which the first participant was enrolled.

The investigator will collect 8 mL (one and one half teaspoons) of blood one time only. The investigator may also collect the patient's past medical history, test results and disease treatment.

NCT01815996
Principal SponsorUniversity of Florida
Last updated: November 21, 2018
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

130 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-Control

These studies compare people who have a disease (cases) with those who don't (controls). The goal is to look back at previous exposures or risk factors to identify what might have contributed to the disease.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Cardiovascular DiseasesEmbolismHeart DiseasesImmune System DiseasesInfarctionIschemiaLung DiseasesNecrosisPathologic ProcessesRespiratory Tract DiseasesPathological Conditions, Signs and SymptomsVascular DiseasesEmbolism and ThrombosisMyocardial IschemiaAutoimmune DiseasesMyocardial InfarctionPulmonary Embolism

Criteria

Inclusion Criteria: Patients must be adults in one of the following categories: Pregnant Suffered a pulmonary embolism within the past 48 hours Myocardial infarction in the past 48 hours Diagnosed with an autoimmune disease Adults age 18-80 Self-declared healthy adults Patients must be willing to undergo a blood draw Patients must provide study-specific informed consent prior to study entry Exclusion Criteria: 1. Patients not meeting the above inclusion criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

5 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Shands Davis Cancer Center

Gainesville, United StatesOpen Shands Davis Cancer Center in Google Maps
CompletedOne Study Center